A Lot-to-Lot Consistency Clinical Trial of PCV13

Summary

A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years. The objective of the study is to evaluate the the Lot-to-Lot consistency, immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind phase IIIb clinical trial.

Timeline

Start

2026-09

Primary completion

2027-03

Completion

2027-03

Drugs

Indications